CJC-1295 is a synthetic, long-acting analogue of growth-hormone-releasing hormone (GHRH). Its defining feature is duration: an albumin-binding design, worked out in animals, keeps it circulating for days rather than minutes. One early-phase human study found it raises growth hormone and IGF-1 for several days, with an estimated half-life of about six to eight days. It is not approved by any regulator, for any use, anywhere.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference, not a protocol. It sets out what the published research on CJC-1295 reports, how much of it is human rather than animal, and what a clean log holds. It gives no dose figure and no schedule, and a section below explains why.
| Property | Value |
|---|---|
| Class / type | Synthetic long-acting analogue of growth-hormone-releasing hormone (GHRH) (Teichman et al., 2006; Jette et al., 2005) |
| Evidence base | Albumin-binding mechanism characterised in rats (animal). Human data limited to one early-phase (Phase 1) study in healthy adults (human) |
| Half-life | Approximately 5.8 to 8.1 days (estimated), for the long-acting DAC form, from a Phase 1 human study (Teichman et al., 2006) |
| Regulatory status | Not approved in any jurisdiction, for any indication; sold only as a research peptide |
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) engineered to last far longer than the natural hormone. The mechanism was worked out in animals: in rats, the molecule binds covalently to serum albumin, which protects it from rapid breakdown and keeps it circulating — one analysis found it still on the albumin fraction of rat plasma well beyond a day after injection, identifying CJC-1295 as a long-lasting GHRH analogue (Jette et al., 2005). This is animal work, not human.
The main human study is an early-phase (Phase 1) trial in healthy adults aged 21 to 61 (Teichman et al., 2006): a single subcutaneous injection produced sustained, dose-dependent rises in growth hormone of 2- to 10-fold lasting six days or more, and in IGF-1 of 1.5- to 3-fold lasting nine to eleven days. That is genuine human evidence that the compound raises growth hormone and IGF-1, and that the effect is long — but it is where the human story stops: early-phase pharmacology in healthy volunteers, not a demonstration of clinical benefit, and it has not completed late-stage development or been approved.
The candid picture is a well-characterised animal mechanism, one solid early-phase human study, and no approved clinical use. The widely repeated “six-to-eight-day half-life” figure is real and traceable to that human study (Teichman et al., 2006), but it describes how long the compound lingers, not that it is effective or appropriate for any use.
A Phase 1 human study estimated CJC-1295's half-life at 5.8 to 8.1 days for the long-acting form (Teichman et al., 2006). A half-life is the time it takes for half of what is present to clear, and at roughly a week, successive administrations overlap heavily instead of clearing between them — levels build rather than returning to baseline.
Two things follow for record-keeping. Because the compound lingers for days, any effect noticed in a given week reflects what came before it, not just the most recent administration — so the dated history is far more informative than any single entry. And a slow curve makes gaps consequential: a missed administration is a larger disturbance than for a fast-clearing compound, so the log should make an absence obvious. Pepti's half-life calculator draws the decay curve from the value you enter; remember it is the best published human estimate from a single early-phase study, not a fixed constant, so read the curve as indicative.
CJC-1295 has no approved product label, so there is no authorised storage instruction specific to it. What can be said is general, drawn from how approved lyophilised peptides in the same family are handled. Tesamorelin, an approved GHRH analogue supplied as a freeze-dried (lyophilised) powder, is a useful reference point: its labelling directs that the sealed powder be kept in its original carton and protected from light, reconstituted only with the sterile diluent provided, and mixed by rolling the vial gently rather than shaking (tesamorelin prescribing information, US FDA via DailyMed).
As a dry powder in a sealed vial the material is comparatively stable; once a diluent is added it becomes a solution with a limited life, so labels in this family direct that it be used promptly, any unused portion discarded, and used only if clear and free of particles (tesamorelin prescribing information). The exact temperature, diluent and in-use window differ by product, so the only correct source for a given vial is whatever the supplier specifies. A record should capture the date a vial was reconstituted, so its in-use window stays visible.
Here is how Pepti's parts apply, using only figures you already have.
Reconstitution, as arithmetic. If your vial arrived as a lyophilised powder, the reconstitution calculator turns the amount stated on the vial, the volume of diluent you add, and the figure you already have into a draw volume, syringe units, and how many draws the vial holds. Each is a variable you supply; the calculator does the arithmetic, not the figure.
Site rotation. GHRH analogues are given by subcutaneous injection, so the same spot is easy to overuse. Pepti remembers your last site and moves you through a fixed 12-site rotation; the injection site rotation guide explains the zone system in full.
Decay from your own half-life. The half-life decay calculator charts how a starting amount falls over successive half-lives — but only from a half-life you enter. For CJC-1295, enter the roughly six-to-eight-day estimate above if you want a curve, and read the result as indicative.
CJC-1295 is not an approved medicine. There is no approved label anywhere, which means no authorised dose, no approved schedule, and no titration guidance outside a research setting. Any figure published as a “typical dose” for an unapproved compound is not drawn from an approved source, because none exists — it comes from forum consensus, vendor copy, or someone's reading of a study protocol run under monitoring conditions that do not apply elsewhere.
Pepti converts a figure you already have into a draw volume and syringe units, tracks what is left in each vial, and remembers where the last injection went. It does not supply the figure, and it will not, for this compound or any other. Pages that publish dose tables for research peptides are publishing folklore with the typography of evidence; the figure belongs to you and whoever directs your use, and the arithmetic is what we are for.
A CJC-1295 log has few entries, so each one carries more weight. A record worth keeping holds the following.
CJC-1295 is a synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH). In rats it was identified as a GHRH analogue that binds covalently to serum albumin, which keeps it circulating far longer than natural GHRH (Jette et al., 2005). In healthy adults, a single subcutaneous injection raised growth hormone and IGF-1 for several days (Teichman et al., 2006). It is not an approved medicine.
No. CJC-1295 is not approved by any regulator, in any country, for any use, and is sold only as a research peptide. In December 2024 the US Food and Drug Administration's Pharmacy Compounding Advisory Committee reviewed CJC-1295, including the long-acting DAC form, as a bulk drug substance nominated for pharmacy compounding, a process that applies only to substances that are not approved drug products (FDA, 2024).
A phase 1 human study estimated the half-life of CJC-1295 at 5.8 to 8.1 days for the long-acting form (Teichman et al., 2006). That is why the compound is described as long-acting: at roughly a week, successive administrations overlap heavily rather than clearing between them. The estimate comes from one early-phase study, so treat any decay curve built on it as indicative.
No. Pepti supplies no dose figures for CJC-1295 or for anything else. It records the figure you already have from whoever directs your use, converts it into a draw volume and syringe units, tracks what is left in each vial, and keeps the site sequence. The arithmetic is ours; the figure is not.
This page is a reference on published evidence and record-keeping. It does not recommend CJC-1295 or any other substance, and it provides no dose figure, no titration amount, and no schedule. CJC-1295 is not approved for any use.
The Pepti peptide tracker for iPhone keeps the log, the site sequence, the vial count and your own notes in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store